Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON41527
NL-OMON41527
Completed
Phase 2

Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancer - IMPACT breast

niversitair Medisch Centrum Groningen0 sites200 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsmammacarcinomametastatic breast cancer10006291

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
mammacarcinoma
Sponsor
niversitair Medisch Centrum Groningen
Enrollment
200
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •\- Patient with first presentation of MBC, regardless of ER and HER2 status of the primary tumor, who is eligible for first\-line systemic therapy.
  • •\- Patient with non\-rapidly progressive MBC, not requiring urgent initiation of chemotherapy, based on clinician's evaluation
  • •\- Patients in whom standard imaging work\-up of MBC was recently (\<\= 28 days) performed
  • •\- Patient with measurable or clinically evaluable (bone only) disease on recent standard work up of MBC are eligible.
  • •\- Metastatic lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures.
  • •\- Performance score 0\-2

Exclusion Criteria

  • •\- Contraindications for systemic treatment (as will be assigned based on biopsy and experimental scan results), either chemotherapy, hormonal therapy or anti\-HER2 therapy, based on clinical judgment of treating medical oncologist and patient history.
  • •\- Pregnant or lactating women.
  • •\- Rapidly progressive (visceral) disease requiring rapid initiation of chemotherapy.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2013-000551-41-NLniversity Medical Center Groningen
Recruiting
Not Applicable
Developing personalized cancer therapy strategy through genomic analysis in liquid biopsy and cancer tissue from metastatic gastrointestinal cancer patientsNeoplasms
KCT0003511Pusan National University Hospital210
Recruiting
Not Applicable
POINTING: Towards patient-tailored cancer immunotherapy supported by a multifaceted predictive signature composed of integrative omics and molecular imaging.NSCLCskin cancer (melanoma)10027476
NL-OMON51740niversitair Medisch Centrum Groningen200
Completed
Not Applicable
utritional therapy for cancer patientHealth Condition 1: C509- Malignant neoplasm of breast of unspecified site
CTRI/2021/03/031634Rajiv Gandhi university of Health Sciences Grant in aid for advanced research project100
Active, not recruiting
Phase 1
The BARCODE 2 Study – The Use of Genetic Profiling to Guide Prostate Cancer TreatmentProstate CancerMedDRA version: 19.0Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2016-000869-23-GBThe Institute of Cancer Research